GC
ACER

Guggenheim Capital’s Acer Therapeutics Inc ACER Stock Holding History

Guggenheim Capital’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-122
Closed -$17K – 3153
2014
Q2 		$17K Sell
122
-13
-10% -$1.72K ﹤0.01% 3169
2014
Q1 		$21K Buy
+135
New +$20.5K ﹤0.01% 3226

Other funds holding ACER

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Guggenheim Capital's ACER Position: Q3 2014 in Review

Guggenheim Capital sold out of Acer Therapeutics Inc (ACER) in Q3 2014, closing a stake of 122 shares — an estimated $17K sold.

Guggenheim Capital first reported a position in ACER in Q1 2014 and held it in 2 quarters. The position peaked at $21K in Q1 2014. 18 funds tracked by Wall St. Rank hold ACER as of Q3 2014.

  • Guggenheim Capital reported no remaining Acer Therapeutics Inc position as of Q3 2014 after selling out during the quarter.
  • Guggenheim Capital sold 122 Acer Therapeutics Inc shares in Q3 2014, an estimated $17K.
  • Guggenheim Capital first reported a position in Acer Therapeutics Inc in Q1 2014 and held it in 2 quarters.
  • Guggenheim Capital's Acer Therapeutics Inc position peaked at $21K in Q1 2014.
  • 18 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2014.

Based on Guggenheim Capital's 13F filing for Q3 2014, filed 14 Nov 2014.